Medizinische Universitätsklinik, Baldingerstraße, 35033 Marburg/Lahn, Germany.
Eur J Radiol. 2011 Nov;80(2):169-74. doi: 10.1016/j.ejrad.2009.11.012. Epub 2009 Dec 11.
The aim of this study was to compare the value of contrast-enhanced ultrasonography (CEUS) with standard B-mode ultrasound (US) for diagnosis of splenic lymphoma involvement.
From 04/2005 to 10/2008 n=250 lymphoma patients were investigated by standard B-mode US. A homogeneous splenic echotexture was found in 199 patients (79%). To clarify the benefit of CEUS in this group a pilot series was performed with 16 of the 199 lymphoma patients. All patients with an abnormal splenic echotexture on standard B-Mode US (n=51) including focal hypoechoic splenic lesions (n=41) and an inhomogeneous splenic texture (n=10) were studied by CEUS. CEUS data were retrospectively evaluated. The diagnoses included indolent lymphoma (n=27), aggressive lymphoma (n=14), and Hodgkin's disease (n=10). Number and size of lesions were determined by B-mode US and CEUS. The visualisation of splenic lymphoma involvement by CEUS in comparison to B-mode US was classified as worse, equal, or better.
All patients with a homogeneous spleen on B-mode US (n=16) had no visible focal lesions on CEUS. Study patients with focal lesions (n=41) had a hypoechoic (n=22) or isoechoic (n=19) enhancement during the arterial phase, and a hypoechoic enhancement during the parenchymal phase (n=41). The visualisation of focal splenic lymphoma was equal (n=32), better (n=6), or worse (n=3). In all study patients with an inhomogeneous spleen on B-mode US (n=10) no focal lesions were found by CEUS and the value of CEUS therefore was classified as worse.
CEUS has no clear advantage for diagnosis of splenic lymphoma involvement.
本研究旨在比较超声造影(CEUS)与标准 B 型超声(US)对脾脏淋巴瘤受累的诊断价值。
2005 年 4 月至 2008 年 10 月,250 例淋巴瘤患者接受了标准 B 型 US 检查。199 例患者(79%)脾脏回声均匀。为了明确 CEUS 在这组患者中的优势,我们对其中的 199 例淋巴瘤患者中的 16 例进行了一项试点研究。所有在标准 B 型 US 上显示脾脏回声异常的患者(n=51),包括局灶性低回声脾脏病变(n=41)和不均匀的脾脏质地(n=10),均接受了 CEUS 检查。回顾性评估 CEUS 数据。诊断包括惰性淋巴瘤(n=27)、侵袭性淋巴瘤(n=14)和霍奇金病(n=10)。通过 B 型 US 和 CEUS 确定病变的数量和大小。CEUS 对脾脏淋巴瘤受累的显示与 B 型 US 进行比较,分为较差、相等或较好。
所有在 B 型 US 上脾脏回声均匀的患者(n=16)在 CEUS 上均未见可见的局灶性病变。有局灶性病变的患者(n=41)在动脉期呈低回声(n=22)或等回声(n=19)增强,在实质期呈低回声增强(n=41)。局灶性脾脏淋巴瘤的显示为相等(n=32)、较好(n=6)或较差(n=3)。在所有在 B 型 US 上脾脏回声不均匀的患者(n=10)中,CEUS 均未发现局灶性病变,因此 CEUS 的价值被归类为较差。
CEUS 对诊断脾脏淋巴瘤受累没有明显优势。